-
1
-
-
25444437498
-
0,1% tacrolimus ointment in the treatment of discoid lupus erythematosus
-
Heffernan M, Nelson M, Smith D, Chung J. 0,1% tacrolimus ointment in the treatment of discoid lupus erythematosus. Arch Dermatol. 2005; 141: 1170-1.
-
(2005)
Arch Dermatol
, vol.141
, pp. 1170-1171
-
-
Heffernan, M.1
Nelson, M.2
Smith, D.3
Chung, J.4
-
2
-
-
4444347666
-
Pimecrolirnus 1% cream for cutaneous lupus erythematosus
-
Kreuter A, Gambichler T, Breuckmann F, Pawlak FM, Stücker M, Bader A et al. Pimecrolirnus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol. 2004; 51: 407-10.
-
(2004)
J Am Acad Dermatol
, vol.51
, pp. 407-410
-
-
Kreuter, A.1
Gambichler, T.2
Breuckmann, F.3
Pawlak, F.M.4
Stücker, M.5
Bader, A.6
-
3
-
-
0036434289
-
Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod
-
Gerdsen R, Wenzel J, Uerlich M, Bieber T, Petrow W. Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod. Dermatology. 2002; 205: 416-8.
-
(2002)
Dermatology
, vol.205
, pp. 416-418
-
-
Gerdsen, R.1
Wenzel, J.2
Uerlich, M.3
Bieber, T.4
Petrow, W.5
-
4
-
-
8344253557
-
Update on the management of cutaneous lupus erythematosus
-
Callen JP. Update on the management of cutaneous lupus erythematosus. Br J Dermatol. 2004; 151: 731-6.
-
(2004)
Br J Dermatol
, vol.151
, pp. 731-736
-
-
Callen, J.P.1
-
5
-
-
22944467522
-
Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: Results of a retrospective study in 43 patients
-
Wenzel J, Brähler S, Bauer R, Bieber T, Tüting T. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol. 2005; 153: 157-62.
-
(2005)
Br J Dermatol
, vol.153
, pp. 157-162
-
-
Wenzel, J.1
Brähler, S.2
Bauer, R.3
Bieber, T.4
Tüting, T.5
-
6
-
-
0034941002
-
Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil
-
Goyal S, Nousari HC. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol. 2001; 45: 142-4.
-
(2001)
J Am Acad Dermatol
, vol.45
, pp. 142-144
-
-
Goyal, S.1
Nousari, H.C.2
-
7
-
-
0028047560
-
Traitement du lupus érythémateux chronique par la sulfasalazine
-
Delaporte E, Piette F, Bourjot D, Duneton-Bitbol V, Bergoend H. Traitement du lupus érythémateux chronique par la sulfasalazine. Presse Med. 1994; 23: 95-6.
-
(1994)
Presse Med
, vol.23
, pp. 95-96
-
-
Delaporte, E.1
Piette, F.2
Bourjot, D.3
Duneton-Bitbol, V.4
Bergoend, H.5
-
8
-
-
0031316203
-
Traitement du lupus érythémateux chronique par la sulfasalazine: 11 observations
-
Delaporte E, Catteau B, Sabbagh N, Gosselin P, Breuillard F, Doutre MS et al. Traitement du lupus érythémateux chronique par la sulfasalazine: 11 observations. Ann Dermatol Venereol. 1997; 124: 151-6.
-
(1997)
Ann Dermatol Venereol
, vol.124
, pp. 151-156
-
-
Delaporte, E.1
Catteau, B.2
Sabbagh, N.3
Gosselin, P.4
Breuillard, F.5
Doutre, M.S.6
-
9
-
-
0030898186
-
NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus
-
Sabbagh N, Delaporte E, Marez D, Lo-Guidice JM, Piette F, Broly F. NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus. Pharmacogenetics. 1997; 7: 131-5.
-
(1997)
Pharmacogenetics
, vol.7
, pp. 131-135
-
-
Sabbagh, N.1
Delaporte, E.2
Marez, D.3
Lo-Guidice, J.M.4
Piette, F.5
Broly, F.6
-
11
-
-
14544308953
-
Successful treatment of lichen planus with sulfasalazine in 20 patients
-
Bauza A, Espana A, Gil P, Lloret P, Vazquez Doval FJ. Successful treatment of lichen planus with sulfasalazine in 20 patients. Int J Dermatol 2005; 44: 158-62.
-
(2005)
Int J Dermatol
, vol.44
, pp. 158-162
-
-
Bauza, A.1
Espana, A.2
Gil, P.3
Lloret, P.4
Vazquez Doval, F.J.5
-
12
-
-
84996119291
-
Discoid erythematosus responsive to sulphasalazine
-
Carmichael AJ, Paul CJ. Discoid erythematosus responsive to sulphasalazine. Br J Dermatol. 1991; 125: 291.
-
(1991)
Br J Dermatol
, vol.125
, pp. 291
-
-
Carmichael, A.J.1
Paul, C.J.2
-
13
-
-
0029913960
-
Efficacy of sulfasalazine in discoid lupus erythematosus
-
Artuz F, Lenk N, Deniz N, Alli N. Efficacy of sulfasalazine in discoid lupus erythematosus. Int J Dermatol. 1996; 35: 746-8.
-
(1996)
Int J Dermatol
, vol.35
, pp. 746-748
-
-
Artuz, F.1
Lenk, N.2
Deniz, N.3
Alli, N.4
-
14
-
-
84858913857
-
Traitement du lupus érythémateux cutané résistant par la sulfasalazine: Rapport bénéfice-risque à évaluer
-
Lagrange S, Piette JC, Becherel PA, Cacoub P, Chosidow O, Francès C. Traitement du lupus érythémateux cutané résistant par la sulfasalazine: rapport bénéfice-risque à évaluer. Ann Dermatol Venereol 1998; 125(Suppl 3): S42-S43.
-
(1998)
Ann Dermatol Venereol
, vol.125
, Issue.3 SUPPL.
-
-
Lagrange, S.1
Piette, J.C.2
Becherel, P.A.3
Cacoub, P.4
Chosidow, O.5
Francès, C.6
-
15
-
-
0036786888
-
Sulphasalazine and mesalazine: Serious adverse reactions reevaluated on the basis of suspected adverse reaction reports to the Committee on safety of medicines
-
Ransford RAJ, Langman MJS. Sulphasalazine and mesalazine : serious adverse reactions reevaluated on the basis of suspected adverse reaction reports to the Committee on safety of medicines. Gut. 2002; 51: 536-9.
-
(2002)
Gut
, vol.51
, pp. 536-539
-
-
Ransford, R.A.J.1
Langman, M.J.S.2
-
16
-
-
0028880443
-
Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis
-
Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995; 333: 1600-7.
-
(1995)
N Engl J Med
, vol.333
, pp. 1600-1607
-
-
Roujeau, J.C.1
Kelly, J.P.2
Naldi, L.3
Rzany, B.4
Stern, R.S.5
Anderson, T.6
-
17
-
-
0022541810
-
Sulphasalazine for rheumatoid arthritis: Toxicity in 774 patients monitored for one to 11 years
-
Amos RS, Pullar T, Bax DE, Situnayake D, Capell HA, McConkey B. Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. Br Med J. 1986; 293: 420-3.
-
(1986)
Br Med J
, vol.293
, pp. 420-423
-
-
Amos, R.S.1
Pullar, T.2
Bax, D.E.3
Situnayake, D.4
Capell, H.A.5
McConkey, B.6
-
18
-
-
0015916139
-
Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype
-
Das KM, Eastwood MA, McManus JPA, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med. 1973; 289: 491-5.
-
(1973)
N Engl J Med
, vol.289
, pp. 491-495
-
-
Das, K.M.1
Eastwood, M.A.2
McManus, J.P.A.3
Sircus, W.4
-
19
-
-
0022537791
-
Side effects profile on 200 patients with inflammatory arthritides treated with sulphasalazine
-
Farr M, Scott DGI, Bacon PA. Side effects profile on 200 patients with inflammatory arthritides treated with sulphasalazine. Drugs. 1986; 32: 49-53.
-
(1986)
Drugs
, vol.32
, pp. 49-53
-
-
Farr, M.1
Scott, D.G.I.2
Bacon, P.A.3
-
22
-
-
0026505574
-
Axonal neuropathy and salazosulfapyridine: Slow-acetylator phenotype
-
Blin O, Sangla I, Jouglard J, Cottin C, Pellissier JF, Serratrice G. Axonal neuropathy and salazosulfapyridine : slow-acetylator phenotype. Rev Neurol. 1992; 148: 154-6.
-
(1992)
Rev Neurol
, vol.148
, pp. 154-156
-
-
Blin, O.1
Sangla, I.2
Jouglard, J.3
Cottin, C.4
Pellissier, J.F.5
Serratrice, G.6
-
23
-
-
0032616812
-
Acute pancreatitis induced by drugs derived from 5-aminosalicylic acid: Case report and review of the literature
-
Decocq G, Gras-Champel V, Vrolant-Mille C, Delcenserie R, Sauve L, Masson H et al. Acute pancreatitis induced by drugs derived from 5-aminosalicylic acid : case report and review of the literature. Therapie. 1999; 54: 41-8.
-
(1999)
Therapie
, vol.54
, pp. 41-48
-
-
Decocq, G.1
Gras-Champel, V.2
Vrolant-Mille, C.3
Delcenserie, R.4
Sauve, L.5
Masson, H.6
-
24
-
-
10844279275
-
N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse effects
-
Tanigawara Y, Kita T, Aoyama N, Gobara M, Komada F, Sakai T et al. N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse effects. Biol Pharm Bull. 2002; 25: 1058-62.
-
(2002)
Biol Pharm Bull
, vol.25
, pp. 1058-1062
-
-
Tanigawara, Y.1
Kita, T.2
Aoyama, N.3
Gobara, M.4
Komada, F.5
Sakai, T.6
-
25
-
-
1242314682
-
N-acetyltransferase 2 genotype-related efficacy of sulphasalazine in patients with rheumatoid arthritis
-
Kumagai S, Komada F, Kita T, Morinobu A, Ozaki S, Ishida H et al. N-acetyltransferase 2 genotype-related efficacy of sulphasalazine in patients with rheumatoid arthritis. Pharmaceutic Res. 2004; 21: 324-9.
-
(2004)
Pharmaceutic Res
, vol.21
, pp. 324-329
-
-
Kumagai, S.1
Komada, F.2
Kita, T.3
Morinobu, A.4
Ozaki, S.5
Ishida, H.6
-
26
-
-
0034091884
-
Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis
-
Wadelius M, Stjernberg E, Wiholm BE, Rane A. Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis. Pharmacogenetics. 2000; 10: 35-41.
-
(2000)
Pharmacogenetics
, vol.10
, pp. 35-41
-
-
Wadelius, M.1
Stjernberg, E.2
Wiholm, B.E.3
Rane, A.4
-
27
-
-
0037863063
-
Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine
-
Ohtani T, Hiroi A, Sakurane M, Furukawa F. Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine. Br J Dermatol. 2003; 148: 1035-9.
-
(2003)
Br J Dermatol
, vol.148
, pp. 1035-1039
-
-
Ohtani, T.1
Hiroi, A.2
Sakurane, M.3
Furukawa, F.4
-
28
-
-
0037803498
-
Sulphasalazine-induced leucopenia in a patient with renal dysfunction
-
Teshima D, Hino B, Makino K, Yano T, Itoh Y, Joh Y et al. Sulphasalazine-induced leucopenia in a patient with renal dysfunction. J Clin Pharmacol Ther. 2003; 28: 239-42.
-
(2003)
J Clin Pharmacol Ther
, vol.28
, pp. 239-242
-
-
Teshima, D.1
Hino, B.2
Makino, K.3
Yano, T.4
Itoh, Y.5
Joh, Y.6
-
29
-
-
0036896055
-
Adverse effects of sulphasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene
-
Tanaka E, Taniguchi A, Urano W, Nakajima H, Matsuda Y, Kitamura Y et al. Adverse effects of sulphasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol 2002; 29: 2492-9.
-
(2002)
J Rheumatol
, vol.29
, pp. 2492-2499
-
-
Tanaka, E.1
Taniguchi, A.2
Urano, W.3
Nakajima, H.4
Matsuda, Y.5
Kitamura, Y.6
-
30
-
-
0028781678
-
Sulfasalazine ou interféron dans le traitement du lupus: La poule, l'œuf, le loup
-
Piette JC, Francès C, Papo T, Godeau P. Sulfasalazine ou interféron dans le traitement du lupus : la poule, l'œuf, le loup. Presse Med. 1994; 23: 956.
-
(1994)
Presse Med
, vol.23
, pp. 956
-
-
Piette, J.C.1
Francès, C.2
Papo, T.3
Godeau, P.4
-
31
-
-
0030724065
-
Predisposing factors in sulphasalazine-induced systemic lupus erythematosus
-
Gunnarsson I, Kanerud L, Pettersson E, Lundberg I, Lindblad S, Ringertz B. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Br J Rheumatol. 1997; 36: 1089-94.
-
(1997)
Br J Rheumatol
, vol.36
, pp. 1089-1094
-
-
Gunnarsson, I.1
Kanerud, L.2
Pettersson, E.3
Lundberg, I.4
Lindblad, S.5
Ringertz, B.6
-
32
-
-
0029003640
-
Sulphasalazine-induced autoimmune abnormalities in patients with rheumatic disease
-
Laversuch CJ, Collins DA, Charles PJ, Bourke BE. sulphasalazine-induced autoimmune abnormalities in patients with rheumatic disease. Br J Rheumatol. 1995; 34: 435-9.
-
(1995)
Br J Rheumatol
, vol.34
, pp. 435-439
-
-
Laversuch, C.J.1
Collins, D.A.2
Charles, P.J.3
Bourke, B.E.4
-
33
-
-
0032952111
-
Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years
-
Gordon MM, Porter DR, Capell HA. Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years. Ann Rheum Dis. 1999; 58: 288-90.
-
(1999)
Ann Rheum Dis
, vol.58
, pp. 288-290
-
-
Gordon, M.M.1
Porter, D.R.2
Capell, H.A.3
-
34
-
-
0027427575
-
Follow-up of patients with double stranded DANN antibodies induced by sulphasalazine during the treatment of inflammatory rheumatic diseases
-
Mielke H, Wildhagen K, Mau W, Zeidler H. Follow-up of patients with double stranded DANN antibodies induced by sulphasalazine during the treatment of inflammatory rheumatic diseases. Scand J Rheumatol. 1993; 22: 299-301.
-
(1993)
Scand J Rheumatol
, vol.22
, pp. 299-301
-
-
Mielke, H.1
Wildhagen, K.2
Mau, W.3
Zeidler, H.4
-
35
-
-
85066729356
-
Changes in antinuclear serology in patients with spondylarthropathy under sulphasalazine treatment
-
De Keyser F, Mielants H, Praet J, Goemaere S, Veys EM. Changes in antinuclear serology in patients with spondylarthropathy under sulphasalazine treatment. Br J Rheumatol. 1993; 32: 251-6.
-
(1993)
Br J Rheumatol
, vol.32
, pp. 251-256
-
-
De Keyser, F.1
Mielants, H.2
Praet, J.3
Goemaere, S.4
Veys, E.M.5
-
36
-
-
0025372354
-
A one-year, open, prospective study of sulphasalazine in the treatment of rheumatoid arthritis: Adverse reactions and clinical response in relation to laboratory variables, drug and metabolite serum levels, and acetylator status
-
Chalmers IM, Sitar DS, Hunter T. A one-year, open, prospective study of sulphasalazine in the treatment of rheumatoid arthritis: adverse reactions and clinical response in relation to laboratory variables, drug and metabolite serum levels, and acetylator status. J Rheumatol. 1990; 17: 764-70.
-
(1990)
J Rheumatol
, vol.17
, pp. 764-770
-
-
Chalmers, I.M.1
Sitar, D.S.2
Hunter, T.3
|